Startups · AI

Head of Biology

Parallel Bio · San Francisco, CA · On-site

← All jobs
About Parallel Bio

Using the immune system to cure disease. Backed by Y Combinator.

About the role

Drug discovery has a translation problem: more than 95% of drugs that succeed in animal models fail in humans. We're building the alternative: human-first drug discovery, powered by organoids and AI, running on real human biology from the very first experiment.

What they're looking for

  • A pre-IND regulatory expert. You understand how the FDA operates at the discovery and translational stages: what data packages are best up to IND, what bridging studies look like, and how to present them
  • VP-caliber. Opinionated, decisive, comfortable with high-stakes judgment calls. You can say "we are not going to do that, here's why" with the same conviction as "we are doing this, here's why."
  • Energized by the bet. You see human-first drug discovery as one of the most important shifts in pharmaceutical science in a generation, and you want to be the person calling the scientific shots
More about this role

Drug discovery has a translation problem: more than 95% of drugs that succeed in animal models fail in humans. We're building the alternative: human-first drug discovery, powered by organoids and AI, running on real human biology from the very first experiment.

Our platform is 87% concordant with clinical patient data - a vast improvement over the 3% translational success rate of animals. We’ve demonstrated the ability to model immunotoxicology, immunogen stimulation, and two autoimmune diseases with more on the way. Numerous pharma partners including 3 Fortune 500 companies are already using the platform. We've raised ~$30M from AIX Ventures, Marc Benioff, Jeff Dean, and Y Combinator. With the FDA Modernization Act 3.0 and the FDA's March 2026 validation framework, the regulatory tailwinds only continue to get stronger.

The opportunity ahead of the company is generational: build the first scaled engine for generating real human biological data, and use it to fundamentally change how medicines are discovered.

Parallel Bio's platform can model essentially any aspect of human immunology: infectious disease, cancer, autoimmunity, allergy, transplantation, and beyond. As we scale...

Read the full posting on Parallel Bio's site ↗

Science

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.